From the Food and Drug Administration
Overview
Authors
Affiliations
Watson C, Sekhar G, Thomas S Front Drug Deliv. 2024; 3:1113493.
PMID: 38482132 PMC: 7615738. DOI: 10.3389/fddev.2023.1113493.
Enantiospecific antitrypanosomal in vitro activity of eflornithine.
Boberg M, Cal M, Kaiser M, Jansson-Lofmark R, Maser P, Ashton M PLoS Negl Trop Dis. 2021; 15(7):e0009583.
PMID: 34252098 PMC: 8297939. DOI: 10.1371/journal.pntd.0009583.
Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.
Gerner E, Bruckheimer E, Cohen A J Biol Chem. 2018; 293(48):18770-18778.
PMID: 30355737 PMC: 6290143. DOI: 10.1074/jbc.TM118.003343.
Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
Dauchy F, Bonhivers M, Landrein N, Dacheux D, Courtois P, Lauruol F PLoS Negl Trop Dis. 2016; 10(11):e0005125.
PMID: 27855164 PMC: 5113867. DOI: 10.1371/journal.pntd.0005125.
The development of drugs for treatment of sleeping sickness: a historical review.
Steverding D Parasit Vectors. 2010; 3(1):15.
PMID: 20219092 PMC: 2848007. DOI: 10.1186/1756-3305-3-15.